艾司氯胺酮干预与剖宫产术后产后抑郁及镇痛关联的系统综述与Meta分析
该系统综述与Meta分析检索多个数据库至2023年8月,纳入11项使用爱丁堡产后抑郁量表评估的随机对照试验,比较艾司氯胺酮对剖宫产术后产后抑郁与疼痛的效果。结果显示艾司氯胺酮组产后一周内产后抑郁风险较低(RR 0.45,95%CI 0.33-0.62),术后爱丁堡产后抑郁量表评分较低(MD -1.64,95%CI -2.14至-1.14),48小时内疼痛评分显著下降(MD -0.71,95%CI -0.89至0.52),并增加术中不良神经与精神事件风险但不损害健康,术后与对照组无显著差异。作者认为艾司氯胺酮可能短期降低产后抑郁风险并辅助镇痛,但需更多高质量证据确认。
要点
- 艾司氯胺酮组产后一周内产后抑郁风险低于对照组(RR 0.45,95%CI 0.33-0.62)。
- 术中艾司氯胺酮维持术后较低的EPDS评分(MD -1.64,95%CI -2.14至-1.14)。
- 艾司氯胺酮增加术中不良神经与精神事件风险但不损害健康,术后与对照组无显著差异。
核心结论
- 艾司氯胺酮可能短期降低剖宫产患者产后抑郁风险,并作为辅助镇痛有效协助疼痛管理。
- 由于缺乏更高质量证据,需要更有说服力的证据来确认艾司氯胺酮改善产后恢复的价值。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Cochrane Library、Web of Science、CNKI和万方数据库,从建库至2023年8月。
- 纳入所有剖宫产且随机接受艾司氯胺酮干预的随机对照试验,不限年龄或种族。
- 采用Cochrane协作工具进行质量评价,使用Review Manager 5.3软件进行统计分析,结果以均数差及95%置信区间表示,采用随机效应或固定效应模型合并,使用标准I2统计量评估异质性。
- 共纳入11项使用爱丁堡产后抑郁量表评估产后抑郁的随机对照试验。
主要发现
- 艾司氯胺酮组术后一周内产后抑郁风险低于对照组(风险比0.45,95%置信区间0.33-0.62)。
- 术中艾司氯胺酮维持术后较低的EPDS评分(均数差-1.64,95%置信区间-2.14至-1.14)。
- 艾司氯胺酮与48小时内疼痛评分显著下降相关(均数差-0.71,95%置信区间-0.89至0.52)。
- 艾司氯胺酮增加术中不良神经与精神事件风险但不损害健康,术后与对照组相比无显著差异。
关键数值与推荐
- 产后抑郁风险:艾司氯胺酮组风险比0.45(95%置信区间0.33-0.62),低于对照组。
- 术后EPDS评分:艾司氯胺酮组均数差-1.64(95%置信区间-2.14至-1.14),低于对照组。
- 48小时内疼痛评分:艾司氯胺酮组均数差-0.71(95%置信区间-0.89至0.52),低于对照组。
- 术中不良神经与精神事件:艾司氯胺酮组风险增加但不损害健康;术后与对照组无显著差异。
临床怎么用
- 作者认为艾司氯胺酮可能短期降低剖宫产患者产后抑郁风险。
- 作者认为艾司氯胺酮作为辅助镇痛可有效协助疼痛管理。
- 作者指出需更多有说服力的证据来确认艾司氯胺酮改善产后恢复的价值。
局限性
- 原文指出缺乏更高质量证据,需要更有说服力的证据来确认艾司氯胺酮改善产后恢复的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to compare the efficacy and safety of the use of esketamine to reduce the risk for postpartum depression and pain after cesarean delivery. DATA SOURCES: Literature searches were conducted in PubMed, Embase, Cochrane Library, Web of Science, CNKI, and Wan fang from inception to August 2023. STUDY ELIGIBILITY CRITERIA: The eligibility criteria were all randomized controlled trials of people who underwent a cesarean delivery and who were randomized to receive esketamine interventions irrespective of age or ethnicity. The outcomes that were assessed included the incidence of postpartum depression and the Edinburgh Postnatal Depression Scale score within 7 days and at 28 to 42 days after delivery, the pain score (visual analog scale or numerical rating scale, 0-10), the consumption of opioids, and intraoperative and postoperative adverse events. METHODS: The Cochrane collaboration's tool was used for quality appraisal of the included studies. Statistical analysis of the data was performed using Review Manager 5.3 software, and the results were expressed as mean differences with 95% confidence intervals. Assessments were pooled using a random-effects or fixed-effects model. Study heterogeneity was assessed using the standard I2 statistic. RESULTS: Among the 11 included randomized controlled trials that used the Edinburgh Postnatal Depression Scale for postpartum depression assessment, patients in esketamine group had a lower risk for postpartum depression within a week of surgery (risk ratio, 0.45; 95% confidence interval, 0.33-0.62). Intraoperative use of esketamine maintained a lower Edinburgh Postnatal Depression Scale score after surgery (mean difference, -1.64; 95% confidence interval, -2.14 to -1.14). Esketamine was associated with a beneficial effect in terms of the other outcomes, including a significant decline in pain score within 48 hours (mean difference, -0.71; 95% confidence interval, -0.89 to 0.52). Esketamine increased the risk for adverse neurologic and mental events during surgery without harming health, and there was no significant difference after delivery when compared with the control group. CONCLUSION: Esketamine may reduce the risk for postpartum depression among patients who are undergoing cesarean delivery in the short term. In addition, as an adjunct to reduce analgesia, esketamine also effectively assists in pain management. Because of the lack of more high-quality evidence, we need more compelling evidence to confirm the value of esketamine in improving postpartum recovery.
引用
- Ma S, Dou Y, Wang W, et al. Association between esketamine interventions and postpartum depression and analgesia following cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2024. PMID: 38262519. doi:10.1016/j.ajogmf.2023.101241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。